摘要
目的:探讨环孢素A治疗再生障碍性贫血的临床疗效。方法:选择118例再生障碍性贫血患者,随机分为治疗组和对照组各59例,其中治疗组采用用环孢素A进行治疗,对照组采用司坦唑醇治疗,治疗后,比较两组患者的临床疗效、血液指标变化情况和不良反应发生情况。结果:治疗组的总有效率为89.83%,显著高于对照组的总有效率76.27%,差异有统计学意义(P<0.05);两组患者的白细胞数、血红蛋白量和血小板数均较治疗前显著升高,且治疗后治疗组较对照组均显著高于对照组(P<0.05);治疗组的不良反应率为32.20%,高于对照组的27.12%,差异无统计学意义(P>0.05)。结论:采用环孢素A治疗再生障碍性贫血的临床疗效较佳,不良反应发生率略高,但均为一过性。
Objective To investigate the clinical efficacy of cyclosporin A in the treatment of aplastic anemia.Methods 118 cases of aplastie anemia patients were randomly divided into the treatment group and the control group,and 59 eases in each group,in which the treatment group was treated with eyclosporine A treatment,and the control group using stanozolol treatment.After treatment,the clinical efficacy,blood indicators of changes in circumstances and adverse events between the two groups of patients were compared.Results The total effective rate of the treatment group was 89.83%,significantly higher than the total efficiency of 76.27%(/~ 〈 0.05).The white blood cell count,hemoglobin and platelet count were significantly increased than before treatment,and after treatment,the treatment group compared with the control group,it was significantly higher(P 〈 0.05).The adverse reaction rate of the treatment group was 32.20%,higher than 27.12%,but there was no significant difference(P 〉 0.05). Conclusion The clinical efficacy of cyclosporine A in the treatment of aplastic anemia is better, and it is with a slightly higher incidence of adverse reactions,but it is transient.
出处
《吉林医学》
CAS
2013年第8期1432-1433,共2页
Jilin Medical Journal